NPO-2270 ameliorates cardiac dysfunction more effectively than enalapril in two experimental models of heart failure.
Sevilla and Barcelona, 27 April 2022 – Landsteiner Genmed (LGM), a biopharmaceutical company focused on the development of cysteine proteases inhibitors, and the Cardiovascular Diseases Laboratory of the Vall d’Hebron Institute of Research (VHIR) led by Drs I. Ferreira and J. Inserte first presented efficacy data on NPO-2270 in the American College of Cardiology Meeting (ACC22, Washington DC, April 2022).
NPO-2270 is a potent oral inhibitor of key cysteine proteases participating in the development of cardiac hypertrophy and its progression to adverse remodelling and cardiac dysfunction.
Results obtained in two models of heart failure in mice show that NPO-2270 prevents the progression of hypertrophy and fibrosis and ameliorates cardiac dysfunction, and support the potential of the compound to treat post-infarct heart failure.
Dr Enrique Vazquez-Tatay, Chief Executive Officer and Co-Founder of LGM, commented: “We are very excited to publish such key encouraging preclinical data on NPO-2270. These findings provide a strong rationale for using selective cysteine protease inhibitors to treat heart failure, a clear medical need causing high social and economic impact. We continue to progress our compound to the clinical stage.”
Dr Javier Inserte, PI at VHIR, commented: “Our group has a long-track record reporting evidence about the key role of certain cysteine proteases (i.e. calpains) on cardiovascular diseases. Our fruitful collaboration with Landsteiner Genmed confirms the potential of these targets to develop future drugs for heart failure”.
The abstract has been published online and is available at: